WaveMan
WaveMan · Company
EVMN · Evommune, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

EVMN Evommune (EVMN) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0002044725
Quote by TradingView
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
77
13F, latest reported quarter
Conversions, 180 days
6
Codes C/M, not in net · $189.8K priced

What the filings say about EVMN

Insiders, 180 days
-$2.1M net sold
2 buyers · 6 sellers · 0% of sales under a 10b5-1 plan

Evommune insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Evommune, Inc. insiders sold a net $2.1M of stock across 16 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Carver Kyle
Chief Financial Officer
BUY
2026-07-10 SECtraded 2026-07-08
1,000
$13.3K
-57.6%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on May 28, 2026.
  • The trade is 1.7% of the 60,335 shares held after it.
  • 1 other insider bought within 30 days.
  • 77 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Carver Kyle bought about $13.3K of EVMN on Jul 8, 2026; 1 other insider bought within 30 days and 77 funds added in the latest 13F quarter.
KIRSCH ARTHUR S
Director
BUY
2026-07-08 SECtraded 2026-07-07
10,000
$133.0K
-62.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 10,000 shares held after it.
  • 1 other insider bought within 30 days.
  • 77 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director KIRSCH ARTHUR S bought about $133.0K of EVMN on Jul 7, 2026; 1 other insider bought within 30 days and 77 funds added in the latest 13F quarter.
Drew Janice Suzann
Chief of Dev. Operations
SELL
2026-06-24 SECtraded 2026-06-22
20,000
$452.6K
-78.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 29.5% of the 67,794 shares held after it.
  • 5 other insiders sold within 30 days.
  • 77 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief of Dev. Operations Drew Janice Suzann sold about $452.6K of EVMN on Jun 22, 2026, the largest insider sale at the company on our record; 5 other insiders sold within 30 days and 77 funds added in the latest 13F quarter.
Patel Jeegar Pravinkumar
Chief Scientific Officer
SELL
2026-06-24 SECtraded 2026-06-22
1,488
$33.5K
-78.7%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 1, 2026.
  • The trade is 3.2% of the 46,403 shares held after it.
  • 5 other insiders sold within 30 days.
  • 77 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Patel Jeegar Pravinkumar sold about $33.5K of EVMN on Jun 22, 2026; 5 other insiders sold within 30 days and 77 funds added in the latest 13F quarter.
Pena Luis C.
President & CEO
SELL
2026-06-24 SECtraded 2026-06-22
7,438
$168.9K
-78.7%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 1, 2026.
  • The trade is 1.2% of the 630,458 shares held after it.
  • 5 other insiders sold within 30 days.
  • 77 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Pena Luis C. sold about $168.9K of EVMN on Jun 22, 2026; 5 other insiders sold within 30 days and 77 funds added in the latest 13F quarter.
16 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 11 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$2.1M over 180 days
below 71% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
77 funds bought in last quarter
more than 59% of Pharma & Biotech
Revenue
+85.7% year over year
more than 83% of Pharma & Biotech
Margin
-529.8% net margin
below 78% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
17.8% of the float short (float per yahoo 2026-10-27) · 3.4 days to cover · settled 2026-10-15
more than 71% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 9 in the prior 90
Why it matters
The absence is the signal: 9 sales in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch EVMN

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-74.6%12M
-75%-31%+12%+56%2025-112026-012026-032026-052026-062026-082026-10 2025-11-07 · LSP 7 Cooperative UA bought $25.0M2025-11-07 · Verduyn-van Weegen Felice Isabel bought $25.0M2025-11-07 · RA CAPITAL MANAGEMENT, L.P. bought $18.5M2025-11-07 · RA CAPITAL MANAGEMENT, L.P. bought $1.5M2026-06-22 · Drew Janice Suzann sold $452.6K2026-05-28 · Carver Kyle sold $415.1K2026-06-01 · Pena Luis C. sold $381.7K2026-06-01 · Patel Jeegar Pravinkumar sold $379.5K2026-05-28 · Moss Gregory S. sold $324.7K2026-06-22 · Pena Luis C. sold $168.9K2026-07-07 · KIRSCH ARTHUR S bought $133.0K2026-06-02 · Cohen David E sold $110.3K2026-06-22 · Patel Jeegar Pravinkumar sold $33.5K2025-12-19 · Hopfner Robert Lorne bought $17.4K2026-07-08 · Carver Kyle bought $13.3K2026-06-02 · Cohen David E sold $12.8K2026-06-22 · JANICE DREW filed to sell $427.2K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns EVMN: institutional holders (13F)

13F holdings, latest reported quarter
EQT Fund Management S.a r.l.
5,288,313 sh
$70.3M
RA CAPITAL MANAGEMENT, L.P.
3,494,638 sh
$46.4M
Pivotal bioVenture Partners Investment Advisor LLC
1,926,943 sh
$25.6M
JPMORGAN CHASE & CO
1,553,132 sh
$23.4M
RTW INVESTMENTS, LP
1,502,235 sh
$20.0M

Congress trades in EVMN

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

EVMN planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
JANICE DREW
Filed 2026-06-22
$427.2K

EVMN mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Eventide Healthcare & Life Sciences Fund
$12.5M position · as of 2026-06-30
0.7%
Virtus Biotech Clinical Trials Etf
$176.3K position · as of 2026-07-31
0.4%
JPMorgan Small Cap Growth Fund
$7.4M position · as of 2026-06-30
0.3%
American Century Small Cap Growth Insights ETF
$31.3K position · as of 2026-05-31
0.2%
Multi-Manager Small Cap Equity Strategies Fund
$2.2M position · as of 2026-05-31
0.2%
Small Cap Growth Fund
$894.3K position · as of 2026-05-31
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
6
Phase 2
1 active
What changed recently
Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
2026-10-03 · Completion moved 2026-07 → 2026-07-23
Phase 2
Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
2026-10-03 · Active Not Recruiting → Completed
Phase 2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $2.1M sold by insiders over 180 days, 77 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

EVMN financials

Revenue growth
+85.7%
XBRL, annual
Net margin
-529.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$10.0M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-946.7%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$74.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-178.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-31.4%
TTM net income over ending balance 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-35.8%
operating income (EBIT proxy) over ending balance 2026-06-30 minus current liabilities
P/E, trailing
0.93x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
n/a
no debt line filed
FCF yield
-40.1%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-12
Revenue$13.0M$7.0M
Operating income-$81.1M-$70.0M
Net income-$68.9M-$66.8M
EPS (diluted)-11.22-45.29
Operating cash flow-$76.4M-$58.2M
Cash$44.1M$16.3M
SEC XBRL, fiscal years, as known on 2026-10-28

EVMN Stock Sonar score 5/7 axes

Find similar shapesCompare

EVMN ranks highest on growth (83rd percentile) and institutional and government (59th), and lowest on risk and compliance (19th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
47
Inputs
  • Return on equity-178.0% · 19 pct, sector of 545
  • Return on assets-31.4% · 59 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-35.8% · 64 pct, sector of 576
Growth
83
Inputs
  • Revenue growth, YoY+85.7% · 83 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
55
Inputs
  • Net Form 4 buying (codes P and S), 180d-$2.1M · 28 pct, sector of 429
  • Insider buyers, 180d2 · 81 pct, sector of 438
Institutional and government
59
Inputs
  • Funds adding, latest quarter77 · 59 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
19
Inputs
  • Short interest, % of float+17.8% · 19 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

EVMN filings, in plain words

Are Evommune insiders buying or selling EVMN?

In the 180 days to 2026-10-28, Evommune insiders were net sellers, a net $2.1M: $146.3K of purchases and $2.3M of sales reported on Form 4, by 2 buyers and 6 sellers.

Read the full summary

In the 180 days to 2026-10-28, Evommune insiders were net sellers of EVMN, a net $2.1M across purchases and sales reported on Form 4 by 2 buyers and 6 sellers. Sales outweighed purchases more than tenfold by value. None of the 9 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies